Stifel reiterates Glaukos stock rating on strong Epioxa survey

Stifel reiterated its Buy rating and $190 price target on Glaukos after a survey indicated Epioxa procedures rose fourfold to 124 in Q3 2026 from 31 in Q2, implying roughly $30 million-$44 million of Q3 Epioxa sales. Respondents projected 310 Q4 procedures; even under a more conservative assumption, Stifel estimates Q4 Epioxa revenue of $65 million-$70 million, supported by improving insurance coverage. The bullish view follows Glaukos's Q2 revenue beat of $185.6 million, up 49.5% year over year versus $151.13 million consensus, and a raised full-year sales outlook, although the stock is flagged as overvalued relative to estimated fair value.

Analysis

GKOS now trades on the slope of Epioxa adoption rather than on the legacy glaucoma franchise, making reimbursement conversion and repeat ordering more important than headline procedure counts. The survey-derived ramp is directionally constructive but is based on a small, potentially selection-biased physician sample; the key earnings question is whether reported revenue confirms broad geographic penetration and whether gross margin holds as commercial support expands. A miss versus an elevated implied launch trajectory would likely drive multiple compression disproportionately because the stock already reflects a premium growth outcome.

Near term, the asymmetry is positive only if management converts payer-progress commentary into measurable covered lives, lower prior-authorization friction, and durable sequential utilization. Over 1-3 months, the principal catalyst is a revenue/guide raise that validates the product mix shift; over 6-18 months, a competing cross-linking entrant could expand the diagnosed and treated market but also reduce GKOS's pricing and first-mover advantage. The more constructive second-order view is that a larger referral and screening ecosystem may raise total procedure volume faster than it fragments share, though that outcome should not be assumed before competitive clinical data and commercial terms are clear.

Consensus appears to be treating rapid procedural growth as a smooth extrapolation. The underappreciated risk is a payer-driven pause: clinics can perform early cases under narrow coverage or exceptional approvals, while scaled adoption depends on reimbursement consistency that often arrives unevenly by region and plan. Conversely, if GKOS demonstrates that Epioxa is additive to, rather than cannibalistic of, its existing ophthalmology call point, operating leverage could exceed current expectations as fixed salesforce costs are absorbed across iDose and corneal products.

Key Decisions for Investors

• Initiate only a starter long GKOS on a pullback toward $150-155 or after the next results validate revenue conversion; target $190-200 over 3-6 months, with a hard thesis review if the stock breaks $140 or management does not reaffirm sequential Epioxa growth.
• For defined risk, use a 6-9 month GKOS $170/$200 call spread rather than outright calls. This expresses upside from a guidance raise while limiting exposure to a post-results de-rating; avoid if implied volatility is materially elevated ahead of earnings.
• Track three pre-earnings datapoints: covered-life expansion, the ratio of procedures to recognized Epioxa sales, and salesforce/SG&A growth. Treat weak payer commentary or a revenue-per-procedure shortfall as a signal to reduce exposure even if procedure estimates remain strong.
• Do not short prospective cross-linking competition solely on clinical-readout risk: a successful entrant may enlarge the addressable market and referral funnel. Reassess GKOS's long-term position when competitor efficacy, retreatment rates, pricing, and payer access are independently disclosed.